NCT07608432Phase 3Recruiting

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2030-12Estimated

Enrollment · participants90Estimated

Source updated2026-05-27Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Duchenne Muscular Dystrophy (DMD); Muscular Dystrophy, Duchenne; Muscular Dystrophy (DMD); DMD; Muscular Dystrophies; Muscular Dystrophy in Children; Muscular Dystrophy, Duchenne Type; Muscular Dystrophy, Duchenne and Becker Types; Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy); Genetic Disease, Inborn; Genetic Disease, X-Linked; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neuromuscular Diseases (NMD)

Treatments or interventions studied

Zeleciment Rostudirsen (DYNE-251)Drug
PlaceboDrug

Primary outcomes · main study measures

measure: Rise From Floor (RFF) velocity; timeFrame: Baseline, Week 73

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history